HHS Issues Its Interim Peptide Compounding Policy

Six peptides that have never been tested for safety or effectiveness in a large human trial are now the subject of an actual signed federal notice, not a leak or a filing sitting at the White House budget office waiting for a decision.

From OMB review to a dated notice

On October 28, the Department of Health and Human Services filed an "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" under docket HHS-OASH-2026-0496, scheduled to run in the Federal Register on October 30, according to RAPS's Regulatory Focus and AJMC's summary of the notice. The notice says HHS does not intend to pursue enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound six unapproved peptide bulk substances: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500.

The Journal covered this plan when it was a drafting-stage filing at the White House Office of Management and Budget earlier in October. What changed this week is the paper trail itself: a signed notice with a docket number, a scheduled Federal Register publication date, and a public comment window, rather than a policy still awaiting sign-off.

What "enforcement discretion" is, and isn't

The FDA's Section 503A list of approved compounding bulk substances normally grows through notice-and-comment rulemaking, a process that can take years and that these six peptides have not completed. Enforcement discretion skips that step without changing the underlying law: HHS is choosing where to direct its enforcement resources, not declaring the peptides approved. Per AJMC and Healio's report on the notice, the notice itself states it establishes no rights for any person, is not binding on HHS, and is not FDA approval of any peptide. It also says HHS may revisit the policy, in whole or in part, if a safety signal or product-quality problem comes up.

The conditions attached are procedural rather than clinical: the bulk peptide must come from an FDA-registered facility, carry a certificate of analysis that meets criteria in FDA guidance, and compounders must report serious adverse events and product-quality problems to the agency. A prescription is required. None of that substitutes for the clinical trials an approved drug goes through.

What's known, what isn't, and who's objecting

The policy follows a July 2026 vote by the FDA's Pharmacy Compounding Advisory Committee, which recommended six of seven peptides under review for the 503A list (it rejected emideltide). FDA's own career scientists had argued against listing any of them, citing thin or absent human data, according to reporting cited by both RAPS and AJMC. Before that vote, the FDA had added eight new committee members, several of whom press reports tied to peptide prescribing or promotion — appointments that some agency officials had internally questioned.

The Partnership for Safe Medicines, a drug-safety advocacy group, filed a citizen petition the week before the notice asking FDA to disregard the committee's vote entirely. In a statement issued the same day as the notice, the group said the committee was reconstituted in ways it argues violate the Federal Advisory Committee Act and the Ethics in Government Act, and that "many newly appointed PCAC members appear to have conflicts of interest directly related to the peptide substances under consideration." Its statement called the move one that "leaves Americans in a grey area as to whether peptides are safe or not." On the other side, HHS frames the policy as a safer alternative to peptides bought from unregulated foreign sellers, and advocacy groups including the American Academy of Peptide Medicine requested meetings with OMB while the notice was under review, per AJMC.

What remains genuinely unresolved: whether a 503A listing granted through enforcement discretion, rather than completed rulemaking, will survive a legal challenge; what the two-week public comment period on docket HHS-OASH-2026-0496 will turn up; and whether any of the six peptides generate the kind of adverse-event reports that the notice says could trigger a reversal.

What this means for researchers

Nothing about this notice changes what is or isn't established about BPC-157, epitalon, KPV, MOTS-c, semax or TB-500 in humans. It changes who can legally compound them, under what paperwork, while the FDA's own scientific review process continues on a separate and much slower track. A peptide moving through enforcement discretion is not a peptide with a settled safety record; it is a peptide a cabinet secretary has decided not to spend enforcement resources chasing, which is a different and more fragile kind of status.

For anyone tracking the research literature rather than the regulatory fight, the practical marker to watch is the comment docket closing and whatever the FDA's own scientists say in response, not the notice's publication date. The agency that voted against listing these peptides in July hasn't changed its underlying assessment; the policy around it changed instead. That gap between the science and the policy is worth remembering the next time either side describes this as settled.

The Journal will keep following this docket as it moves, the way it has since the policy was still an anonymous sourcing story in early October.